	US 12,263,216 B2
	Cancer antigens and methods
George Kassiotis, London (GB); George Young, London (GB); Jan Attig, London (GB); Bram Snijders, London (GB); David Perkins, London (GB); Fabio Marino, London (GB); and Nicola Ternette, London (GB)
Assigned to The Francis Crick Institute Limited, London (GB); and Enara Bio Limited, Oxfordshire (GB)
Filed by The Francis Crick Institute Limited, London (GB); and Enara Bio Limited, Oxford (GB)
Filed on Apr. 16, 2021, as Appl. No. 17/232,597.
Application 17/232,597 is a continuation of application No. PCT/GB2019/052980, filed on Oct. 18, 2019.
Claims priority of application No. 18201634 (EP), filed on Oct. 19, 2018.
Prior Publication US 2021/0353729 A1, Nov. 18, 2021
Int. Cl. A61K 39/39 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 16/32 (2006.01); C12N 5/0783 (2010.01); C12N 5/0784 (2010.01)

CPC A61K 39/39 (2013.01) [A61K 39/4611 (2023.05); A61K 39/46449 (2023.05); A61K 39/464491 (2023.05); A61P 35/00 (2018.01); C07K 14/4748 (2013.01); C07K 16/32 (2013.01); C12N 5/0636 (2013.01); C12N 5/0639 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/55538 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/6031 (2013.01); A61K 2039/876 (2018.08); A61K 2239/57 (2023.05); C07K 2319/00 (2013.01)]

3 Claims

1. A composition comprising an isolated polypeptide and an immunostimulant selected from the group consisting of aluminum phosphate, saponins, immunostimulatory oligonucleotides, aminoalkyl glucosaminide 4-phosphates, lipopolysaccharides, 3-de-O-acylated monophosphoryl lipid A (3D-MPL), toll-like receptor 4 (TLR4) ligands, toll-like receptor 7 (TLR7) ligands, toll-like receptor 8 (TLR8) ligands, toll-like receptor 9 (TLR9) ligands, interleukin 12 (IL-12), and interferons, wherein:

the isolated polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 1, 11-14, 55-57 and 73-74.